<?xml version="1.0" encoding="UTF-8"?>
<p id="para0025">The PREVENT-HD trial was designed to answer the hypothesis that initiation of prophylactic-dose rivaroxaban early in the course of COVID-19 infection, prior to hospitalization, will reduce the risk of thrombosis, hospitalization, and death, and to evaluate the safety of such a strategy. It has been designed to answer this hypothesis with the rigor of a double-blind, randomized event driven design, but with innovative aspects intended to improve feasibility, reduce risk to study participants and study staff, and maximize data transfer and informatics capabilities.</p>
